Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Stéphane Cattan, Julien Edeline, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Olivier Rosmorduc, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo
Peter Vogel, Julien Edeline, Sadahisa Ogasawara, Masatoshi Kudo, R. Finn, D. Palmer, Chris Verslype, Vittorina Zagonel, L. Fartoux, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Aristine Cheng, B. Daniele, T. Yau, A. Wang, Ken Hatogai, A.B. Siegel, S. Cattan
Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L. Chan, Jennifer J. Knox, Shukui Qin, Abby B. Siegel, Michael Chisamore,
Discussion(0)
No comments yet. Be the first to comment.